| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Pyridostigmine | Pyridostigmine EP Impurity A | VE006883 | View CAS 51581-32-9 |
| Pyridostigmine | Pyridostigmine EP Impurity B | VE006884 | View CAS 31034-86-3 |
Pyridostigmine Impurities
| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Pyridostigmine | Pyridostigmine EP Impurity A | VE006883 | View CAS 51581-32-9 |
| Pyridostigmine | Pyridostigmine EP Impurity B | VE006884 | View CAS 31034-86-3 |
[rfq_list]
| Catalogue No. | VE006884 |
| CAS No. | 31034-86-3 |
| Molecular Formula | C6H8BrNO |
| Molecular Weight | 190.04 |
| Parent drug | Pyridostigmine |
| IUPAC Name | 3-Hydroxy-1-methylpyridinium bromide |
| Synonyms | Pyridostigmine Related Compound B |
| References | Sci-Hub, Pyridostigmine bromide exposure creates chronic, underlying neuroimmune disruption in the gastrointestinal tract and brain that alters responses to palmitoylethanolamide in a mouse model of Gulf War Illness. Neuropharmacology, 108264, 10.1016/j.neuropharm.2020.108264. (2020). Sci-Hub.se. https://sci-hub.se/https://doi.org/10.1016/j.neuropharm.2020.108264 |
| Status | In-stock |
| ListName | Pyridostigmine EP Impurity B |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
